Should you buy Geron stock now?
Yes, the technical signal for Geron is currently BUY. Geron trades at $1.59 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.014 with falling momentum (signal: 0.015); RSI is at 66.1 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $4.25 points to 167.3% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Geron stock?
The average analyst price target for Geron is $4.25. The current price is $1.59, which gives an upside of 167.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $3.83 and $4.68.
Is Geron a dividend stock?
No, Geron does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Geron stock?
Geron is rated as a stock with high risk. the annual standard deviation is 63.5%, which classifies the stock as high risk.
Is Geron overvalued?
No, Geron is considered undervalued based on the analyst price target (167.3% upside). Geron has the following valuation ratios: a P/S ratio of 4.4, a P/B ratio of 3.6. The analyst price target suggests that the stock is undervalued by 167.3%.
Is Geron overbought?
No, Geron is not overbought. RSI is at 66.1 (neutral zone). The technical indicators show: RSI is at 66.1 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 11.5% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next Geron earnings report?
The date of the next earnings report for Geron has not been published yet. Check the company's investor calendar for updates.
Is Geron shorted?
Yes, Geron is shorted with 10.9% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Geron stock?
Yes, insiders are net buyers of Geron – they are buying more shares than they are selling. Over the last 3 months, insiders have made 1 purchases and 0 sales. On a net basis, 7,812 $ worth of shares were bought. Across the last 20 reported transactions, the split is 12 purchases and 8 sales, with a net 8,034,681 $ sold. Active buyers include Spiegel Robert J., LAWLIS V BRYAN, Ziegler James and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Geron a good stock?
Based on our total score, Geron is rated as a poor stock with a total score of 36 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 21/100, Quality: 19/100, Momentum: 69/100. In addition: analysts see 167.3% upside to the price target; technical signal: Buy. Whether Geron is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Geron stock?
The outlook for Geron based on current data: the average analyst price target is $4.25 (+167.3%); the stock is in an uptrend (above SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Geron stock rising?
Geron is rising right now. The technical indicators show: the price is 11.5% above the 20-day average; short interest is 10.9% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Geron go?
The average analyst price target for Geron is $4.25, which corresponds to a potential gain of 167.3% from the current price of $1.59. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Geron fall?
We lack enough history to give a specific floor for Geron. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Geron do?
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelod... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Geron as an investment.
Did Geron raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Geron. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Geron making money or losing money?
No, Geron is currently not making money — the company is losing money with a negative profit margin of -34.3%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Geron go bankrupt?
The bankruptcy risk of Geron is rated as elevated. Altman Z2 (a model for assessing financial distress) is -6.25 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 5 — which is average. Debt relative to equity is 112% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Geron have a lot of debt?
Geron has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 112%. For the sundhed sector, 80-150% counts as a typical level. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
